Clinical Data CEO and leadership

Andrew J. Fromkin is a President and CEO at Clinical Data Inc.

James Shaffer brings extensive commercial leadership and business experience with over 20 years of experience with large pharmaceuticals, emerging biotechnology and specialty pharmaceutical companies in Infectious Disease, Neurology, Oncology, GI and Pulmonary Care. Prior to joining Eiger, Mr. Shaffer served as Vice President and Chief Commercial Officer for Halozyme Therapeutics from 2011 to 2014 where he was responsible for Sales, Marketing and Business Development overseeing the re-launch of Hylenex® and product development in Diabetes and Oncology. From 2007-2011, Mr. Shaffer was Executive Vice President and Chief Commercial Officer responsible for Sales, Marketing, Business Development and Manufacturing with Clinical Data Inc., who developed Viibryd- a novel antidepressant, which was acquired by Forest Labs for $1.2 billion. James was Vice President of Commercial Operations for New River Pharmaceuticals which developed Vyvance® for the treatment of ADHD and was acquired by Shire for $2.6 billion in 2007. From 2004-2007, he was Senior Director of Commercial Operations for Prestwick Pharmaceuticals overseeing the collaboration with Cambridge Labs for Xenazine®, an orphan CNS specialty product, and responsible for the development of the companies commercial capabilities in the US and Canada. From 2001-2004, Mr. Shaffer was the National Sales Director for InterMune. James spent the first 10 years of his career in numerous sales and marketing positions of increasing responsibility with Merck and GlaxoSmithKline. James Shaffer is a graduate of the Ohio State University where he earned a BS Degree in Economics and Master’s Degree in Business Administration.